Prostate Cancer Therapeutics Global Market Report 2025

The prostate cancer therapeutics market size has grown strongly in recent years. It will grow from $11.92 billion in 2024 to $13.0 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be attributed to several factors, including the rising global incidence of prostate cancer, increased awareness of early cancer screening and diagnostic programs, the growing elderly male population, and a higher demand for personalized and targeted therapies.

The prostate cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $18.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to factors such as rising healthcare expenditure in emerging economies, increasing investments in oncology drugs, greater availability of advanced imaging and diagnostic tools, and the growing adoption of minimally invasive and non-surgical treatments. Key trends in the forecast period include advancements in targeted cancer therapies, the integration of precision cancer medicine, the development of technology-driven diagnostic imaging tools, progress in radioligand-based treatments, and continued advancements in immunotherapy for prostate cancer.

The increasing incidence of prostate cancer is expected to drive the growth of the prostate cancer therapeutics market. Prostate cancer, a disease where malignant cells form in the prostate gland, primarily affects older men. The rise in prostate cancer incidences is largely attributed to the aging population, as the risk of developing the disease increases significantly with age. Longer life expectancy also means more men are living long enough to develop the condition. Prostate cancer therapeutics aim to manage the disease by targeting cancer cells, slowing its progression, and improving the quality of life through treatments such as surgery, radiation, hormone therapy, and newer options such as immunotherapy. For example, in October 2024, the National Health Service (NHS) in the UK reported that cancer diagnoses among men increased by 7% in 2022, from 167,917 to 180,877 cases. A significant portion of this rise was attributed to prostate cancer, which saw a more than 25% increase, reaching 54,732 cases. This growing incidence of prostate cancer is driving the expansion of the prostate cancer therapeutics market.

Leading companies in the prostate cancer therapeutics market are introducing innovative solutions, such as oral once-a-day pills for advanced prostate cancer, to enhance patient compliance and treatment outcomes. These oral pills are taken daily and manage metastatic castration-resistant prostate cancer by inhibiting the effects of testosterone on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based pharmaceutical company, launched Rexigo, India’s first oral once-a-day pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies works by rapidly suppressing testosterone, controlling cancer growth, and offering an improved cardiovascular safety profile. The oral therapy eliminates the need for injectable treatments administered by healthcare providers, offering greater convenience for patients. This launch marks a significant advancement in prostate cancer management in India, providing patients and doctors with a new, safe, cost-effective treatment option.

In June 2024, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired Fusion Pharmaceuticals Inc. for an undisclosed sum. The acquisition strengthens AstraZeneca’s portfolio, enabling the development of next-generation radio conjugates that offer more targeted therapies, potentially replacing traditional chemotherapy and radiotherapy treatments. Fusion Pharmaceuticals, a Canada-based clinical-stage oncology company, specializes in therapies for prostate cancer, particularly targeting metastatic castration-resistant prostate cancer (mCRPC).

Major players in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol‑Myers Squibb Company, F. Hoffmann‑La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Fusion Pharmaceuticals Inc., Ferring B.V., Tolmar Pharmaceuticals Inc.

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prostate cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Prostate cancer therapeutics encompass a range of medical treatments and interventions designed to manage, control, or eliminate prostate cancer, a type of cancer that forms in the prostate gland of men. These therapies aim to slow disease progression, alleviate symptoms, improve quality of life, and, in some instances, achieve remission.

The primary types of therapies in prostate cancer treatment include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and others. Hormonal therapy is a treatment that modifies hormone levels in the body to address conditions such as cancer or hormonal imbalances. This therapy includes various drug classes such as androgen receptor inhibitors, GnRH receptor antagonists, PARP inhibitors, immune checkpoint inhibitors, and more, which can be administered either orally or through injection. These therapies are distributed via hospital pharmacies, retail pharmacies, and online sales, serving various end users, including clinics, hospitals, and other medical facilities.

The prostate cancer therapeutics market research report is one of a series of new reports that provides prostate cancer therapeutics market statistics, including prostate cancer therapeutics industry global market size, regional shares, competitors with a prostate cancer therapeutics market share, detailed prostate cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer therapeutics industry. This prostate cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer therapeutics market consists of revenues earned by entities by providing services such as medical consultation services, diagnostic services, psychosocial support, clinical trials access, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer therapeutics market also includes sales of hormone therapy medications, chemotherapy drugs, immunotherapy products, and targeted therapy drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.